Please assess the completion status of the following clinical trial:

Trial Title: PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Be ≥ 18 and \< 95 years of age.~* Provide written informed consent.~* Diagnosis of nonischemic dilated cardiomyopathy.~* Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.~* Been treated with appropriate maximal medical therapy for heart failure.~* Ejection fraction below 40% and either a left ventricular end diastolic diameter (LVEDD) \> 5.9cm in male subjects, an LVEDD of \> 5.6cm in female subjects or left ventricular end diastolic volume index \> 125 mL/m2~* Be able to undergo an MRI or CT.~Major Exclusion Criteria:~* Baseline glomerular filtration rate equal or \< 45 ml/min/1.73m2.~* Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of nonischemic dilated cardiomyopathy.~* Presence of a prosthetic aortic valve or heart constrictive device.~* Presence of a prosthetic mitral valve.~* Previous myocardial infarction (MI) as documented by a clinical history that will include an elevation of cardiac enzymes and/or ECG changes consistent with MI.~* Diagnosis of nonischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis.~* Previous treatment for post-infarction left ventricular dysfunction including PCI and thrombolytic therapy.~* Documented presence of a known LV thrombus, aortic dissection, or aortic aneurysm.~* Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries.~* Documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less).~* Documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).~* Evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or QTc interval \> 550 ms on screening ECG.~* AICD firing in the past 30 days prior to the procedure~* Be eligible for or require coronary artery revascularization.~* Diabetic with poorly controlled blood glucose levels and/or evidence of proliferative retinopathy.~* Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet values \< 100,000/ul without another explanation.~* Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN.~* Have a coagulopathy condition = (INR \> 1.3) not due to a reversible cause.~* Known, serious radiographic contrast allergy.~* Known allergies to penicillin or streptomycin.~* Organ transplant recipient.~* Have a history of organ or cell transplant rejection~* Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.~* Non-cardiac condition that limits lifespan to \< 1 year.~* On chronic therapy with immunosuppressant medication.~* Serum positive for HIV, hepatitis BsAg, or viremic hepatitis C.~* Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.~* Have a history of drug or alcohol abuse within the past 24 months.~* Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Autologous hMSCs (Type: ACTIVE_COMPARATOR): Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
- Allogeneic hMSCs (Type: ACTIVE_COMPARATOR): Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete